Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 1/20 | 0.48 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.47 |
| ▸ | CASP1 | P29466 | 1/20 | 0.46 |
| ▸ | AR | P10275 | 11/20 | 0.45 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.43 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.43 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24031499 | 0.83 | AR (0.52) | CYP11B2CASP1AR | |
| SCHEMBL24428288 | 0.82 | AR (0.52) | CYP11B2CASP1AR | |
| SCHEMBL3322155 | 0.81 | KEAP1 (0.45) | SCN9AARKEAP1KMT2A | |
| SCHEMBL27880682 | 0.80 | AR (0.46) | CYP11B2CASP1AREGLN2 | |
| SCHEMBL1810935 | 0.80 | AR (0.48) | CYP11B2CASP1AR | |
| SCHEMBL14648841 | 0.80 | KEAP1 (0.53) | KEAP1KMT2A | |
| SCHEMBL29598873 | 0.80 | KEAP1 (0.53) | KEAP1KMT2A | |
| SCHEMBL22873438 | 0.78 | CASP1 (0.47) | CYP11B2CASP1AR | |
| SCHEMBL1813265 | 0.77 | AR (0.46) | CASP1AREGLN2 | |
| SCHEMBL1815502 | 0.77 | AR (0.46) | CASP1AREGLN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180099940-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS, INC. | 2018-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180099940-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | AR, ADRM1, CRBN | SCN9A 4806/4885CYP11B2 270/4885CASP1 3382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.